PHARMACOVIGILANCE (PV) COMPANIES: ENSURING DRUG SAFETY IN PERSONALIZED TREATMENT APPROACHES

Potlapally Laxmi*, Shaik Nazeer, Anujyothi K. and Niharika Nelapatla

ABSTRACT

Pharmacovigilance (PV) companies are essential in ensuring drug safety, especially as medicine shifts towards personalized treatment approaches. This review examines the critical roles PV companies play in monitoring and preventing adverse drug reactions, developing risk management plans, ensuring regulatory compliance, and communicating safety information. Personalized medicine, with its tailored treatments based on genetic, environmental, and lifestyle factors, presents unique challenges for PV, including diverse patient populations, complex data management, increased adverse event reporting, and regulatory hurdles. The article discusses these challenges and explores future directions for PV companies, such as the use of advanced analytics and AI, real-world evidence, collaborative platforms, and patient-centric approaches. By adapting to these evolving demands, PV companies can continue to safeguard public health and enhance the effectiveness of personalized medicine.

Keywords: Pharmacovigilance, Drug Safety, Personalized Medicine, Adverse Event Reporting, Risk Management, Regulatory Compliance, Data Analytics, Artificial Intelligence, Real-World Evidence, Patient-Centric Approaches.